Frontline Options in EGFR-Mutant NSCLC: How the Choice Has Gotten More Complex

In this segment, the panel sets the stage for the frontline treatment landscape in EGFR-mutant non-small cell lung cancer, walking through the options now available and how the conversation with patients has evolved. You will hear why the decision between monotherapy and combination regimens has become more nuanced over time, what factors move clinicians toward intensification, and how patient preference plays a central role in that discussion. The panel addresses the clinical features that most commonly drive the choice toward combination therapy, including performance status, comorbidities, and renal function, and explains why the improvement in outcomes that combination regimens offer must always be weighed against the increased side effect burden they carry.